ライフサイエンスコーパス: left atrial appendage

1 to the first bifurcation and thrombus in the left atrial appendage.

2 ted in the posterior left atrium than in the left atrial appendage.

3 between the left superior pulmonary vein and left atrial appendage.

4 node to the rest of the atria, ending at the left atrial appendage.

5 edominantly because of interference from the left atrial appendage.

6 nary sinus activation during pacing from the left atrial appendage.

7 al ligament disruption, and exclusion of the left atrial appendage.

8 Myofibroblasts were not detected in the left atrial appendage.

9 All patients underwent closure of the left atrial appendage.

10 s (8), septal bags (6) and 1 thrombus in the left atrial appendage.

11 eneity in CV was found between the right and left atrial appendages.

12 pericardial adipose tissues, myocardia, and left atrial appendages.

13 both MV leaflets), interatrial septum (84%), left atrial appendage (86%), and left ventricle (77%) wa

14 NO* concentration was decreased in the left atrial appendage, although NOS expression was not a

15 tural, and morphological features, including left atrial appendage and left atrium-related characteri

16 ither group having incomplete closure of the left atrial appendage and peri-device leak > 5 mm.

17 sinus, the anterior part of the septum, the left atrial appendage and the superior vena cava.

18 CACs and CSCs were cultured from left atrial appendages and blood samples obtained from p

19 ation of AF, emphasize the importance of the left atrial appendage, and consider challenges and futur

20 paced from the left ventricle (VP, n=29) or left atrial appendage (AP, n=12) to induce CM.

21 g, devices such as occluders of a PFO or the left atrial appendage are preferred in patients with an

22 l as premature atrial contractions, from the left atrial appendage at a coupling interval of 200 ms i

23 ths after pulmonary vein isolation, complete left atrial appendage closure (0 mm residual communicati

24 ryoballoon followed by staged interventional left atrial appendage closure (group B).

25 Left atrial appendage closure (LAAC) and nonwarfarin ora

26 As the use of left atrial appendage closure (LAAC) becomes more widesp

27 Long-term data on the safety and efficacy of left atrial appendage closure (LAAC) for stroke preventi

28 dy sought to assess composite data regarding left atrial appendage closure (LAAC) in 2 randomized tri

29 Percutaneous left atrial appendage closure (LAAC) is noninferior to v

30 antithrombotic treatment after transcatheter left atrial appendage closure (LAAC) remains to be deter

31 erapy on coagulation system activation after left atrial appendage closure (LAAC) remains unknown.

32 The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic the

33 Left atrial appendage closure (LAAC) was approved by the

34 Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) was noninferior to

35 was to evaluate the results associated with left atrial appendage closure (LAAC) with the AMPLATZER

36 Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman d

37 ce-related thrombus (DRT) after percutaneous left atrial appendage closure (LAAC).

38 al outcomes beyond 1 year after percutaneous left atrial appendage closure (LAAC).

39 phageal echocardiography during percutaneous left atrial appendage closure (LAAO) and transcatheter e

40 TECT AF trial who underwent attempted device left atrial appendage closure (n=542 patients) and those

41 t and Watchman Device in Patients Undergoing Left Atrial Appendage Closure [SWISS-APERO]; NCT03399851

42 th AF (PROTECT AF) randomized trial compared left atrial appendage closure against warfarin in atrial

43 Safety data on percutaneous left atrial appendage closure arises from centers with c

44 ic Aortic Valve Surgery), and LAACS-2 trial (Left Atrial Appendage Closure by Surgery-2) will help de

45 The implantation of left atrial appendage closure device (WATCHMAN, Boston S

46 ic attack, or thromboembolism) score >/=1, a left atrial appendage closure device is noninferior to l

47 an updated overview of current transcatheter left atrial appendage closure devices and review the res

48 nt had occurred in 65 patients (8.5%) in the left atrial appendage closure group (device group) and i

49 Over the past decade, percutaneous left atrial appendage closure has emerged as a valid alt

50 nvalvular AF at risk for stroke treated with left atrial appendage closure have favorable QOL changes

51 s were successfully isolated with subsequent left atrial appendage closure in 57 patients.

52 e, requiring oral anticoagulation in many or left atrial appendage closure in some.

53 Left atrial appendage closure is a mechanical alternativ

54 Left atrial appendage closure is an alternative to chron

55 Left atrial appendage closure is an established therapy

56 dverse outcomes associated with percutaneous left atrial appendage closure is higher in the real-worl

57 The "local" strategy of left atrial appendage closure is noninferior to "systemi

58 randomly assigned in a 1:1 ratio to undergo left atrial appendage closure or receive oral anticoagul

59 f adverse outcomes and costs of percutaneous left atrial appendage closure procedure in the US.

60 tions, including radiofrequency ablation and left atrial appendage closure procedures for patients wi

61 (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT0085

62 In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Pro

63 fibrillation patients receiving the WATCHMAN left atrial appendage closure technology was designed to

64 Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology, patients with

65 idence for each antithrombotic regimen after left atrial appendage closure to provide tools to guide

66 (PRAGUE-17 [Left Atrial Appendage Closure vs Novel Anticoagulation A

67 The PRAGUE-17 (Left Atrial Appendage Closure vs Novel Anticoagulation A

68 (Left Atrial Appendage Closure vs. Novel Anticoagulation

69 Left Atrial Appendage Closure vs. Novel Anticoagulation

70 catheter-based atrial fibrillation ablation, left atrial appendage closure was associated with a lowe

71 Left atrial appendage closure was evaluated through 12 m

72 six patients with the diagnosis of DRT after left atrial appendage closure were included in the multi

73 conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watc

74 ficant improvement in the safety of Watchman left atrial appendage closure with increased operator ex

75 Left atrial appendage closure with the device (n = 463)

76 [PST] or patient's self-management [PSM] and left atrial appendage closure) are based on the concept

77 t and Watchman Device in Patients Undergoing Left Atrial Appendage Closure) trial, patients with atri

78 s Watchman/FLX Device in Patients Undergoing Left Atrial Appendage Closure), patients undergoing LAA

79 (transcatheter aortic valve implantation and left atrial appendage closure).

80 In more than 10 years experience with left atrial appendage closure, a wide range of antithrom

81 tal of 803 patients were assigned to undergo left atrial appendage closure, and 797 to receive antico

82 rocedure (mitral and tricuspid valve repair, left atrial appendage closure, and paravalvular leak clo

83 , the optimal antithrombotic treatment after left atrial appendage closure, effective on both device-

84 vices and review the results associated with left atrial appendage closure, focusing on procedural an

85 roportion of DRT is detected >6 months after left atrial appendage closure, highlighting the need for

86 During left atrial appendage closure, the estimated dose absorb

87 of experience on the safety of percutaneous left atrial appendage closure.

88 s) with 17.9% being detected >6 months after left atrial appendage closure.

89 the preferred imaging modality to help guide left atrial appendage closure.

90 In the study, we performed left atrial appendage closure.

91 more profound and of longer duration for the left atrial appendage compared with the left atrium as a

92 This study compared left atrial and left atrial appendage contraction velocities in sinus rh

93 In patients, left atrial appendage contraction velocities measured du

94 Peak left atrial appendage contraction velocities were signif

95 unction at all time intervals as assessed by left atrial appendage contraction velocity (LAACV) was s

96 s transcatheter aortic valve replacement and left atrial appendage device occlusion, is being increas

97 d to undergo or not undergo occlusion of the left atrial appendage during surgery; all the participan

98 ty leading to stasis of blood flow following left atrial appendage electrical isolation (LAAEI) could

99 Left atrial appendage elimination may improve catheter a

100 trial fibrillation are depressed relative to left atrial appendage emptying velocities measured durin

101 ersus 4.9 cm, p < 0.0001 and lower mean peak left atrial appendage emptying velocity (LAAEV), 38 vers

102 s and spontaneous echo contrast, we measured left atrial appendage emptying velocity and calculated s

103 ft ventricular diastolic function, and lower left atrial appendage emptying velocity were independent

104 graph-determined transmitral diastolic flow, left atrial appendage emptying, and pulmonary venous flo

105 onary vein, ganglionated plexi ablation, and left atrial appendage excision with optional additional

106 icardial/endocardial ablation procedure with left atrial appendage exclusion for PersAF/LSPersAF.

107 s support LAAO, the randomized LeAAPS trial (Left Atrial Appendage Exclusion for Prophylactic Stroke

108 rm follow-up continues to support a role for left atrial appendage exclusion from the central circula

109 ventricular tachycardia ablation and Lariat left atrial appendage exclusion.

110 s and atrial fibrillation, left atrial size, left atrial appendage flow velocities and thrombus.

111 tients with atrial flutter exhibited greater left atrial appendage flow velocities before cardioversi

112 After cardioversion, left atrial appendage flow velocities decreased compared

113 Left atrial appendages from 239 patients stratified by c

114 The impaired left atrial appendage function after cardioversion was l

115 patients with atrial flutter and to compare left atrial appendage function in the pericardioversion

116 ial fibrillation because of better preserved left atrial appendage function.

117 In this setting, thrombus in the left atrial appendage has been found to be the source of

118 Surgical occlusion of the left atrial appendage has been hypothesized to prevent i

119 tting typically results from thrombus in the left atrial appendage has led to the development of mech

120 AF the intramyocardial blood vessels of the left atrial appendage have an increased CML presence and

121 significantly higher in blood vessels of the left atrial appendage in AF patients as compared to cont

122 tion by Prophylactic Surgical Closure of the Left Atrial Appendage in Patients Undergoing Bioprosthet

123 tion in alcohol intake, and occlusion of the left atrial appendage in patients with atrial fibrillati

124 T AF has, for the first time, implicated the left atrial appendage in the pathogenesis of stroke in a

125 ing atrial fibrillation, suggesting that the left atrial appendage is mechanically "stunned."

126 ency current ablation (group A) or empirical left atrial appendage isolation (LAAI) using the cryobal

127 mly assigned to undergo empirical electrical left atrial appendage isolation along with extensive abl

128 ng the effectiveness of empirical electrical left atrial appendage isolation for the treatment of LSP

129 (Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure O

130 ring repeat procedures, empirical electrical left atrial appendage isolation was performed in all pat

131 umflex coronary artery, and catheters in the left atrial appendage, jugular and carotid vessels.

132 rate, or by equivalent test pacing from the left atrial appendage (LAA) at 5% or 50% greater than th

133 significant effect on blood viscosity in the left atrial appendage (LAA) at low shear rates.

134 standard for the exclusion of thrombi in the left atrial appendage (LAA) before ablation for atrial f

135 The complex structure of the left atrial appendage (LAA) brings limitations to the tw

136 This study investigated the left atrial appendage (LAA) by computed tomography (CT)

137 udy was to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atria

138 ght to determine which surgical technique of left atrial appendage (LAA) closure is most successful b

139 To evaluate the performance and safety of left atrial appendage (LAA) closure procedures with the

140 was to determine the efficacy and safety of left atrial appendage (LAA) closure via a percutaneous L

141 Randomized trials of left atrial appendage (LAA) closure with the Watchman de

142 Drug Administration (FDA) clinical trials of left atrial appendage (LAA) closure, a postimplantation

143 er the empirical electrical isolation of the left atrial appendage (LAA) could improve success at fol

144 the incidence of incomplete ligation of the left atrial appendage (LAA) during mitral valve surgery.

145 Left atrial appendage (LAA) electric isolation is report

146 e impair global LA motion, decreasing LA and left atrial appendage (LAA) emptying fractions, especial

147 hort-term effect of a brief episode of AF on left atrial appendage (LAA) emptying velocity is unknown

148 of this study was to evaluate the impact of left atrial appendage (LAA) exclusion on short-term outc

149 the characterization of left atrial (LA) and left atrial appendage (LAA) flow dynamics in patients wi

150 formed in sinus rhythm at 6 months to assess left atrial appendage (LAA) function were included in th

151 The left atrial appendage (LAA) has been identified as a pre

152 isk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a pri

153 Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic

154 The left atrial appendage (LAA) is an underestimated site of

155 Prophylactic exclusion of the left atrial appendage (LAA) is often performed during ca

156 The left atrial appendage (LAA) is the source of the vast ma

157 Electric left atrial appendage (LAA) isolation (LAAI) may occur d

158 d field ablation for coronary sinus (CS) and left atrial appendage (LAA) isolation and mitral isthmus

159 Transcatheter left atrial appendage (LAA) ligation may represent an al

160 Left atrial appendage (LAA) ligation with the Lariat dev

161 Percutaneous left atrial appendage (LAA) occlusion and novel pharmaco

162 Left atrial appendage (LAA) occlusion provides an altern

163 l Appendage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk o

164 with nonvalvular atrial fibrillation (NVAF), left atrial appendage (LAA) occlusion was noninferior to

165 us transluminal coronary angioplasty (PTCA), left atrial appendage (LAA) occlusion, patent foramen ov

166 th the new Watchman FLX in terms of residual left atrial appendage (LAA) patency or clinical outcomes

167 Left atrial appendage (LAA) procedures have been develop

168 frequency and clinical impact of incomplete left atrial appendage (LAA) sealing and consequent peri-

169 ip of a CHADS(2) score with left atrial (LA)/left atrial appendage (LAA) spontaneous echo contrast, s

170 olic stroke is thought to be associated with left atrial appendage (LAA) thrombi.

171 stroke due almost exclusively to emboli from left atrial appendage (LAA) thrombi.

172 atrial fibrillation (AF) develops persistent left atrial appendage (LAA) thrombus despite optimal ora

173 The left atrial appendage (LAA) was snap-frozen in situ afte

174 Thrombi primarily form in the left atrial appendage (LAA), but the specific role of LA

175 cardioembolic stroke often undergo CT of the left atrial appendage (LAA), for example, to determine w

176 The left atrial appendage (LAA), prone to blood stasis, is a

177 ostic modality of choice for visualizing the left atrial appendage (LAA).

178 ularly, the filling and emptying jets of the left atrial appendage (LAA).

179 ning can produce 4-dimensional images of the left atrial appendage (LAA).

180 the safety and effectiveness of percutaneous left atrial appendage ligation adjunctive to planned pul

181 Percutaneous left atrial appendage ligation adjunctive to pulmonary v

182 ts were randomized in a 2:1 ratio to undergo left atrial appendage ligation and pulmonary vein isolat

183 Primary effectiveness was 64.3% with left atrial appendage ligation and pulmonary vein isolat

184 Left atrial appendage ligation plus pulmonary vein isola

185 all, 404 patients were randomized to undergo left atrial appendage ligation plus pulmonary vein isola

186 ventricular tachycardia ablation and Lariat left atrial appendage ligation that involve the epicardi

187 We evaluated left atrial appendage obliteration in high-risk patients

188 (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational De

189 The Amulet IDE trial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational De

190 The Amulet IDE trial (Amplatzer Amulet Left Atrial Appendage Occluder IDE Trial) was designed t

191 antiplatelet agents, oral anticoagulants or left atrial appendage occlusion (in patients with concom

192 sk, offsetting potential benefits and making left atrial appendage occlusion (LAAO) a potentially pro

193 th different antithrombotic strategies after left atrial appendage occlusion (LAAO) are not well desc

194 Of the 90 patients with stroke, 84 received left atrial appendage occlusion (LAAO) devices.

195 safety of DCCV in patients with endocardial left atrial appendage occlusion (LAAO) devices.

196 Left atrial appendage occlusion (LAAO) has emerged as an

197 The optimal antithrombotic therapy following left atrial appendage occlusion (LAAO) in patients with

198 The role of left atrial appendage occlusion (LAAO) in patients witho

199 Left atrial appendage occlusion (LAAO) is a mechanical s

200 Left atrial appendage occlusion (LAAO) is a method for i

201 Transcatheter left atrial appendage occlusion (LAAO) is an alternative

202 ) treated with anticoagulation compared with left atrial appendage occlusion (LAAO) may be different

203 Left atrial appendage occlusion (LAAO) to prevent stroke

204 Pivotal trials of percutaneous left atrial appendage occlusion (LAAO) used specific pos

205 Background At follow-up CT after left atrial appendage occlusion (LAAO), hypoattenuation

206 of device-related thrombosis (DRT) following left atrial appendage occlusion (LAAO), with the aim of

207 Only few patients (1%) received left atrial appendage occlusion as additional preventive

208 reviewed 301 consecutive patients undergoing left atrial appendage occlusion at Aarhus University Hos

209 ups were novel oral anticoagulants, Watchman left atrial appendage occlusion device (DEVICE), and war

210 d in the early and late 2000's: the Watchman left atrial appendage occlusion device and the Impella p

211 Closure Technology, patients with a WATCHMAN left atrial appendage occlusion device had consistently

212 rsion to exclude left atrial thrombus and in left atrial appendage occlusion device implantation.

213 tial commercial availability of the WATCHMAN left atrial appendage occlusion device overall and in im

214 t classes (bioresorbable coronary scaffolds, left atrial appendage occlusion devices, transcatheter a

215 heart failure, anticoagulation therapy, and left atrial appendage occlusion devices.

216 e volume-outcome relationship for individual left atrial appendage occlusion devices.

217 eneficiaries >=65 years of age who underwent left atrial appendage occlusion from April 1, 2016, to A

218 of stroke, site-specific therapy directed at left atrial appendage occlusion has been now studied for

219 death among Medicare beneficiaries following left atrial appendage occlusion implantation during init

220 oing trials are addressing the usefulness of left atrial appendage occlusion in both primary and seco

221 Left atrial appendage occlusion indication was based on

222 Device-related thrombosis (DRT) following left atrial appendage occlusion is a rare but feared com

223 Left atrial appendage occlusion is an important alternat

224 In-hospital PE during transcatheter left atrial appendage occlusion is infrequent but associ

225 owever, the volume-outcome relationship with left atrial appendage occlusion is poorly understood.

226 tion/atrioventricular junction ablation, and left atrial appendage occlusion may be useful in appropr

227 Long-term outcomes following left atrial appendage occlusion outside clinical trials

228 systemic embolism was lower with concomitant left atrial appendage occlusion performed during the sur

229 re needed to test the safety and efficacy of left atrial appendage occlusion plus anticoagulation ver

230 n hospital and physician volume and WATCHMAN left atrial appendage occlusion procedural success overa

231 The National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry (LAAO) includes

232 st Approval Analysis Plan used data from the Left Atrial Appendage Occlusion registry to identify pat

233 Among 97 185 patients in the Left Atrial Appendage Occlusion registry undergoing WATC

234 e National Cardiovascular Disease Registry's Left Atrial Appendage Occlusion Registry was utilized to

235 in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most commo

236 LAAOS III (Left Atrial Appendage Occlusion Study III) showed that l

237 Left atrial appendage occlusion vs continuation of oral

238 Left atrial appendage occlusion was associated with a lo

239 ients with atrial fibrillation who underwent left atrial appendage occlusion were analysed.

240 Among patients undergoing left atrial appendage occlusion with the first-generatio

241 The Food and Drug Administration approved left atrial appendage occlusion with the Watchman device

242 Left atrial appendage occlusion with WATCHMAN has emerge

243 developments regarding early rhythm control, left atrial appendage occlusion, and novel factor XI inh

244 tral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen oval

245 mboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation cat

246 cological, percutaneous therapies, including left atrial appendage occlusion, for stroke prevention h

247 w of stroke prevention strategies, including left atrial appendage occlusion, in patients with atrial

248 Keywords: Device-related Thrombosis, Left Atrial Appendage Occlusion, Meta-analysis, Transeso

249 patients underwent remapping at the time of left atrial appendage occlusion, which showed CS and LAA

250 hythm after cardioversion, and techniques of left atrial appendage occlusion.

251 is a potential complication of transcatheter left atrial appendage occlusion.

252 Residual leaks are not infrequent after left atrial appendage occlusion.

253 evaluate the impact of residual leaks after left atrial appendage occlusion.

254 haracteristics, and outcomes of PE following left atrial appendage occlusion.

255 Previous observational studies showed left atrial appendage occlusions with the WATCHMAN devic

256 fibrosis on conduction velocity (CV) in the left atrial appendage of patients with AF.

257 g were performed on DNA from lymphocytes and left atrial appendages of 34 patients (25 with AF).

258 as used to study conduction in the right and left atrial appendages of isolated Langendorff-perfused

259 ents were stratified by device size based on left atrial appendage orifice size, and categorized as r

260 lesion using differential coronary sinus and left atrial appendage pacing techniques encounters a pit

261 block using differential coronary sinus and left atrial appendage pacing techniques in patients with

262 was associated with lower odds of persisting left atrial appendage patency (odds ratio, 0.46; 95% CI:

263 Computed tomography-based left atrial appendage patency and PDL were present in 54

264 TEE) or computed tomography (CT), as well as left atrial appendage patency on CT.

265 Neither left atrial appendage patency, nor PDL by CT was associa

266 ontaneous echo contrast (RR 3.7, p < 0.001), left atrial appendage peak flow velocities < or = 20 cm/

267 X2c RNAs were highly correlated in 233 human left atrial appendage samples.

268 Left atrial appendage shear rates were also higher in pa

269 Left atrial appendage stunning also occurs in patients w

270 Left atrial appendage stunning has recently been propose

271 This study sought to determine whether left atrial appendage stunning occurs in patients with a

272 The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in P

273 The Watchman Left Atrial Appendage System for Embolic Protection in P

274 omized clinical trials, PROTECT-AF (Watchman Left Atrial Appendage System for Embolic PROTECTion in P

275 The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in P

276 ) of follow-up from the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in P

277 rawn predominantly from PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in P

278 The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in P

279 systolic function and regional left atrial (left atrial appendage) systolic function upon resumption

280 amber, as well as the pericardium, right and left atrial appendages, the junction of the right atrium

281 Left atrial appendage thrombosis and embolization is the

282 as inserted after induction of GA to exclude left atrial appendage thrombus, define cardiac function,

283 premature AT termination, noninducibility or left atrial appendage thrombus.

284 Left atrial appendage tissue from 33 AF patients and 9 c

285 To address this subject, human left atrial appendage tissues were obtained from 10 pati

286 gned to evaluate the effects of percutaneous left atrial appendage transcatheter occlusion (PLAATO) o

287 s, NYHA functional class, ejection fraction, left atrial appendage velocity, and medications in patie

288 14 mm Hg versus 10 mm Hg; P=0.008), reduced left atrial-appendage velocity (median, 36 cm/s versus 5

289 the PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Preven

290 the PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Preven

291 ar) follow-up of Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Preven

292 The PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Preven

293 tral annulus along the posterior base of the left atrial appendage visualized by selective angiograph

294 ve, tricuspid valve, interatrial septum, and left atrial appendage were obtained, followed by a left

295 Thirty-five left atrial appendages were obtained during AF surgery.

296 In the LAAI group, 77 of 82 left atrial appendages were successfully isolated with s

297 ctural parameters of the left atrium and the left atrial appendage which have been shown to be associ

298 CVL was higher in left atrial appendages with thick compared with thin int

299 on entropy in the posterior left atrium than left atrial appendage, with the decrease in Shannon entr

300 achieved an adequate seal of the neck of the left atrial appendage without significant effect on the